Evidence map›Paper›PMID 41030453›Full record

ReviewFrontiers in immunology2025

TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD.

Rabia S Mousa, Pietro Invernizzi, Joanne L Jones, Hani S Mousa

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rabia S MousaDepartment of Medicine and Surgery, University of Pavia, Pavia, Italy.
Pietro InvernizziDivision of Gastroenterology, Centre for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy.
Joanne L Jones *Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
Hani S Mousa *Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, is an umbrella term used to describe a group of autoimmune conditions characterized by chronic, relapsing inflammation of the gastrointestinal tract. The tumour necrosis factor superfamily member 14 (TNFSF14), also known as LIGHT, is a pleiotropic cytokine with diverse roles in immune regulation. Here, we review the multifaceted involvement of LIGHT in intestinal inflammation, particularly its dual capacity to both promote immune activation and facilitate inflammation resolution in the context of IBD. We explore the molecular mechanisms of LIGHT signalling through its receptors, Herpes Virus Entry Mediator (HVEM) and Lymphotoxin-β Receptor (LTβR), and how these distinct interactions dictate its pro-inflammatory or regulatory functions. Finally, we review the therapeutic potential of targeting this pathway, highlighting the results of recent clinical trials and exploring future strategies aimed at restoring immune homeostasis in patients with IBD.

Indexed as

Inflammatory Bowel DiseasesTumor Necrosis Factor Ligand Superfamily Member 14AnimalsHumansInflammationIntestinal MucosaLymphotoxin beta ReceptorReceptors, Tumor Necrosis Factor, Member 14Signal TransductionLymphotoxin beta ReceptorReceptors, Tumor Necrosis Factor, Member 14TNFSF14 protein, humanTumor Necrosis Factor Ligand Superfamily Member 14BTLA (B and T lymphocyte attenuator)Crohn’s diseaseDcR3 (TNFRSF6B)HVEM (TNFRSF14)inflammatory bowel disease (IBD)LIGHT (TNFSF14)LTβR (Lymphotoxin-β receptor)ulcerative colitis

Identifiers

PMID41030453
PMCPMC12477249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.